Filtered By:
Source: Drug Metabolism and Pharmacokinetics
Infectious Disease: SARS
This page shows you your search results in order of date.
Order by Relevance | Date
Total 13 results found since Jan 2013.
Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs
Drug Metab Pharmacokinet. 2021 Oct 10;41:100424. doi: 10.1016/j.dmpk.2021.100424. Online ahead of print.ABSTRACTNucleic acid therapeutics are developing into precise medicines that can manipulate specific genes. However, the development of safe and effective delivery system for the target cells has remained a challenge. Lipid nanoparticles (LNPs) have provided a revolutionary delivery system that can ensure multiple clinical translation of RNA-based candidates. In 2018, Patisiran (Onpattro) was first approved as an LNP-based siRNA drug. In 2020, during the coronavirus disease 2019 (COVID-19) outbreak, LNPs have enabled the...
Source: Drug Metabolism and Pharmacokinetics - November 10, 2021 Category: Drugs & Pharmacology Authors: Yuta Suzuki Hiroshi Ishihara Source Type: research
